Hepatitis E virus seroprevalence in South Africa: a multi-site study among HIV-negative and HIV-positive adults and age-stratified children (2-17 Years).
Tarun Saluja, Nigus Telele, Elizabeth Hellström...
https://pubmed.ncbi.nlm.nih.gov/42414915/Actively Recruiting
Led by International Vaccine Institute · Updated on 2025-04-29
1040
Participants Needed
3
Research Sites
N/A
Total Duration
Researchers are evaluating the immune response and safety of the Hecolin4 recombinant hepatitis E vaccine in healthy children and adults, including those with and without HIV. The study aims to show that the vaccines immune response in children aged 2 to 17 years is not worse than in healthy adults aged 18 to 45 years. It also compares immune responses between HIV positive and negative adults and assesses safety across different age groups. Participants receive the vaccine or placebo through intramuscular injections according to their age group and HIV status. Adults 18-45 years receive three doses at 0, 1, and 6 months. Children and adolescents are divided into groups receiving either three doses, two doses, or placebo on similar schedules. Blood samples are collected at multiple timepoints before and after vaccination to measure immune response and safety markers. Participants are monitored closely at the study site after each injection for immediate reactions and keep diary cards to record side effects for 7 days. Safety data, including serious and medically attended adverse events, are collected throughout the study. The primary outcome is the rate of immune response measured 4 weeks after the third dose. The study includes follow-up blood collections for up to 2 years to assess long-term immune responses.
CONDITIONS
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
T
Tarun Saluja
S
Sanet Aspinall
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
International Vaccine Institute
Lead Sponsor
Xiamen Innovax Biotech Co., Ltd
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 to 7 months
Participants receive 2 or 3 doses of the Hecolin® hepatitis E vaccine or placebo, given at specified months depending on their group assignment. Vaccinations occur at 0, 1, and 6 months for most groups, with some groups receiving only 2 doses at 0 and 6 months or at 0 and 1 month.
3 vaccination visits plus additional visits for blood sample collection
Duration - Up to 24 months after last dose
Participants are followed up for safety monitoring and immunogenicity assessment, including blood samples collected up to 24 months after the last vaccine dose for some groups.
Multiple follow-up visits for blood samples and safety assessments, including visits at 1, 6, 12, and 24 months after last dose
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
17
Have more questions? Get in touch with our team for quick support
Tarun Saluja, Nigus Telele, Elizabeth Hellström...
https://pubmed.ncbi.nlm.nih.gov/42414915/International Vaccine Institute
Lead Sponsor
Xiamen Innovax Biotech Co., Ltd
Collaborating Sponsor